Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Dianthus Therapeutics, Inc. (DNTH : NSDQ)

• Company Description    Dianthus Therapeutics Inc. is a privately-held, clinical-stage biotechnology company dedicated to advancing the next generation of antibody complement therapeutics. Dianthus Therapeutics Inc., formerly known as Magenta Therapeutics Inc., is based in CAMBRIDGE, Mass. Number of Employees: 78

• Price / Volume Information    Yesterday's Closing Price: $36.28 Daily Weekly Monthly 20 Day Moving Average: 505,113 shares Shares Outstanding: 32.19 (millions) Market Capitalization: $1,167.79 (millions) Beta: 1.56 52 Week High: $40.16 52 Week Low: $13.37 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 5.28% 2.52% 12 Week 74.93% 67.68% Year To Date 66.42% 45.47%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 7 Times Square 43rd Floor - New York,NY 10036 USA ph: 929-999-4055 fax: - ir@dianthustx.com http://www.dianthustx.com

• General Corporate Information    Officers Marino Garcia - President; Chief Executive Officer and Director Alison F. Lawton - Chairman Ryan Savitz - Chief Financial Officer and Chief Business Officer Edward Carr - Chief Accounting Officer Sujay Kango - Director Peer Information Dianthus Therapeutics, Inc. (CORR.) Dianthus Therapeutics, Inc. (RSPI) Dianthus Therapeutics, Inc. (CGXP) Dianthus Therapeutics, Inc. (BGEN) Dianthus Therapeutics, Inc. (GTBP) Dianthus Therapeutics, Inc. (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 252828108 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 09/01/25 Next Expected EPS Date: 03/10/26 Share - Related Items Shares Outstanding: 32.19 Most Recent Split Date: 9.00 (0.06:1) Beta: 1.56 Market Capitalization: $1,167.79 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.96 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-3.62 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 9.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 03/10/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 2.14 Price/Cash Flow: - Price / Sales: 379.52 EPS Growth vs. Year Ago Period: -31.08% vs. Previous Quarter: -10.23% Sales Growth vs. Year Ago Period: -81.77% vs. Previous Quarter: 105.18% ROE 09/30/25 - -33.02 06/30/25 - -34.72 03/31/25 - -29.26 ROA 09/30/25 - -31.08 06/30/25 - -32.72 03/31/25 - -27.87 Current Ratio 09/30/25 - 17.35 06/30/25 - 13.12 03/31/25 - 15.98 Quick Ratio 09/30/25 - 17.35 06/30/25 - 13.12 03/31/25 - 15.99 Operating Margin 09/30/25 - -4,106.04 06/30/25 - -2,364.56 03/31/25 - -1,544.23 Net Margin 09/30/25 - -4,106.04 06/30/25 - -2,364.56 03/31/25 - -1,544.23 Pre-Tax Margin 09/30/25 - -4,106.11 06/30/25 - -2,364.60 03/31/25 - -1,544.26 Book Value 09/30/25 - 16.98 06/30/25 - 9.42 03/31/25 - 10.23 Inventory Turnover 09/30/25 - - 06/30/25 - - 03/31/25 - - Debt-to-Equity 09/30/25 - 0.00 06/30/25 - 0.00 03/31/25 - 0.00 Debt-to-Capital 09/30/25 - 0.00 06/30/25 - 0.00 03/31/25 - 0.00

Powered by Zacks Investment Research ©